Hongjun Gao

Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial

Zhijie Wang, Ying Cheng, Tongtong An et al. · The Lancet Respiratory Medicine · 2018 · 214 citations

Oncology, Tumour Dna, Medicine +10

Enhanced and Differential Capture of Circulating Tumor Cells from Lung Cancer Patients by Microfluidic Assays Using Aptamer Cocktail

Libo Zhao, Chuanhao Tang, Xu Li et al. · Small · 2016 · 129 citations

Multiple Aptamer Combinations, Engineering, Ctc Counts +19

miR-192-5p Silencing by Genetic Aberrations Is a Key Event in Hepatocellular Carcinomas with Cancer Stem Cell Features

Yuanzhuo Gu, Xiyang Wei, Yulin Sun et al. · Cancer Research · 2018 · 95 citations · Full text

Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non–Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling

Mingxiang Ye, Yong Zhang, Hongjun Gao et al. · Clinical Cancer Research · 2017 · 79 citations

A comparison of ARMS and direct sequencing for EGFR mutation analysis and Tyrosine Kinase Inhibitors treatment prediction in body fluid samples of Non-Small-Cell Lung Cancer patients

Yi Liu, Bing Liu, Xiaoyan Li et al. · Journal of Experimental & Clinical Cancer Research · 2011 · 65 citations · Full text